Skip to main content

Table 2 Mortality by reperfusion status and reperfusion-mortality association

From: Access to reperfusion therapy and mortality outcomes in patients with ST-segment elevation myocardial infarction under universal health coverage in Thailand

 Mortality
30-day180-day
1. Mortality, n (%)
 No reperfusion (n = 20,159)7959 (39.5)9105 (45.2)
 PCI (n = 27,983)3600 (12.9)4649 (16.6)
 TBL only (n = 16,405)3071 (18.7)3708 (22.6)
2. Difference in mortalitya, % points (95% CI)
 PCI vs. no reperfusion−26.6* (−25.8, −27.4)−28.6* (−27.7, −29.4)
 TBL only vs. no reperfusion−20.8* (−19.9, − 21.7)−22.6* (− 21.6, − 23.5)
 PCI vs. TBL only−5.9* (−5.1, −6.6)−6.0* (−5.2, −6.8)
3. Difference in probability of dyingb, % points (95% CI)
 PCI vs. no reperfusion−19.6* (− 18.2, − 21.0)−21.1* (− 19.6, − 22.5)
 TBL only vs. no reperfusion−14.1* (− 13.3, − 14.9)−15.1* (−14.3, −16.0)
 PCI vs. TBL only−5.5* (− 2.7, −8.2)−5.4** (− 2.4, −8.5)
  1. * P < 0.001; ** P < 0.01
  2. a Crude analysis without any adjustment for baseline differences between treatment and control groups
  3. b Average treatment effect on the treated (ATET), using PSM between treatment and control groups (See Additional file 1: Figures S4A, B, and C and Table S2 for the covariates predicting treatment probabilities); 95% CI based on robust standard error
  4. CI confidence interval; n number of patients; PCI percutaneous coronary intervention; PSM propensity-score matching; TBL thrombolysis